Suggested remit: To appraise the clinical and cost effectiveness of acalabrutinib and venetoclax with or without obinutuzumab within its marketing authorisation for previously untreated chronic lymphocytic leukaemia.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6232
Provisional Schedule
- Committee meeting: 1:
- 03 February 2026
- Expected publication:
- 22 April 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- AstraZeneca UK (acalabrutinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Chronic Lymphocytic Leukaemia Support Association
- Leukaemia Care
- Leukaemia UK
- Lymphoma Action
- Professional groups
- Association of Cancer Physicians
- British Society for Haematology
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- UK CLL forum
- Associated public health groups
- None
- Comparator companies
- AbbVie (venetoclax) (confidentiality agreement signed, participating)
- BeOne Medicines UK (zanubrutinib) (confidentiality agreement signed, participating)
- Johnson & Johnson Innovative Medicine (ibrutinib) (confidentiality agreement signed, participating)
- Pfizer (rituximab) (confidentiality agreement signed, participating)
- Accord (bendamustine, fludarabine) (confidentiality agreement not signed, not participating)
- Aspen (chlorambucil) (confidentiality agreement not signed, not participating)
- Baxter Healthcare (cyclophosphamide) (confidentiality agreement not signed, not participating)
- Celltrion Healthcare UK (rituximab) (confidentiality agreement not signed, not participating)
- Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating)
- Gilead Sciences (idelalisib) (confidentiality agreement not signed, not participating)
- Roche (obinutuzumab, rituximab) (confidentiality agreement not signed, not participating)
- Sandoz (cyclophosphamide, rituximab) (confidentiality agreement not signed, not participating)
- Sanofi (fludarabine) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating)
- Zentiva (bendamustine) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 July 2025 | Invitation to participate |
| 15 May 2025 | The Department for Health & Social Care has asked NICE to conduct an appraisal of Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-July 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 21 January 2025 - 18 February 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6232 |
| 21 January 2025 | In progress. Scoping commencing |
| 16 December 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual